A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Scientists based in Australia and China have identified a pair of pesky enzymes responsible for prolonging prostate cancer – ...

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

I wake up every morning and thank the Lord to be alive again,” says Ron Roy, 80, from his home in Kelowna. “I hope to make it to 100. My grandmother made it to one month shy of her 100th birthday.” ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Daryl Wilber had his gallbladder removed due to painful gallstones. The regular post-op appointments showed high PSA levels, ...

Former President Joe Biden's treatment for an aggressive form of prostate cancer has entered a new phase. A spokesperson says ...